1
|
Wang R, Gao Y, Wen S, Guo X. BNIPL is a promising biomarker of laryngeal cancer: novel insights from bioinformatics analysis and experimental validation. BMC Med Genomics 2024; 17:45. [PMID: 38302910 PMCID: PMC10832104 DOI: 10.1186/s12920-024-01811-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 01/18/2024] [Indexed: 02/03/2024] Open
Abstract
BACKGROUND Laryngeal cancer (LC) is a malignant tumor with high incidence and mortality. We aim to explore key genes as novel biomarkers to find potential target of LC in clinic diagnosis and treatment. METHODS We retrieved GSE143224 and GSE84957 datasets from the Gene Expression Omnibus database to screen the differentially expressed genes (DEGs). Hub genes were identified from protein-protein interaction networks and further determined using receiver operating characteristic curves and principal component analysis. The expression of hub gene was verified by quantitative real time polymerase chain reaction. The transfection efficiency of BCL2 interacting protein like (BNIPL) was measured by western blot. Proliferation, migration, and invasion abilities were detected by Cell Counting Kit-8, wound-healing, and transwell assays, respectively. RESULTS Total 96 overlapping DEGs were screened out from GSE143224 and GSE84957 datasets. Six hub genes (BNIPL, KRT4, IGFBP3, MMP10, MMP3, and TGFBI) were identified from PPI network. BNIPL was selected as the target gene. The receiver operating characteristic curves of BNIPL suggested that the false positive rate was 18.5% and the true positive rate was 81.5%, showing high predictive values for LC. The expression level of BNIPL was downregulated in TU212 and TU686 cells. Additionally, overexpression of BNIPL suppressed the proliferation, migration, and invasion of TU212 and TU686 cells. CONCLUSION BNIPL is a novel gene signature involved in LC progression, which exerts an inhibitory effect on LC development. These findings provide a novel insight into the pathogenesis of LC.
Collapse
Affiliation(s)
- Rui Wang
- Department of Otolaryngology Head and Neck Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99, Longcheng Street, Taiyuan City, Shanxi Province, 030032, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, 430030, China
| | - Ying Gao
- Department of Otolaryngology Head and Neck Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99, Longcheng Street, Taiyuan City, Shanxi Province, 030032, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, 430030, China
| | - Shuxin Wen
- Department of Otolaryngology Head and Neck Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99, Longcheng Street, Taiyuan City, Shanxi Province, 030032, China.
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, 430030, China.
| | - Xiudong Guo
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, 430030, China
- Department of Head Neck and Breast Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan City, Shanxi Province, 030032, China
| |
Collapse
|
2
|
Wang W, Xiang M, Liu H, Chu X, Sun Z, Feng L. A prognostic risk model based on DNA methylation levels of genes and lncRNAs in lung squamous cell carcinoma. PeerJ 2022; 10:e13057. [PMID: 35356464 PMCID: PMC8958968 DOI: 10.7717/peerj.13057] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 02/13/2022] [Indexed: 02/01/2023] Open
Abstract
Background Recurrence is a risk factor for the prognosis of lung squamous carcinoma (LUSC). DNA methylation levels of RNAs are also associated with LUSC prognosis. This study aimed to construct a prognostic model with high performance in predicting LUSC prognosis using the methylation levels of lncRNAs and genes. Methods The differentially expressed RNAs (DERs) and differentially methylated RNAs (DMRs) between the recurrent and non-recurrent LUSC tissues in The Cancer Genome Atlas (TCGA; training dataset) were identified. Weighted correlation network analysis was performed to identify co-methylation networks. Differentially methylated genes and lncRNAs with opposite expression-methylation levels were used for the screening of prognosis-associated RNAs. The prognostic model was constructed and its performance was validated in the GSE39279 dataset. Results A total of 664 DERs and 981 DMRs (including 972 genes) in recurrent LUSC tissues were identified. Three co-methylation modules, including 226 differentially methylated genes, were significantly associated with LUSC. Among prognosis-associated RNAs, 18 DERs/DMRs with opposite methylation-expression levels were included in the methylation prognostic risk model. LUSC patients with high risk scores had a poor prognosis compared with patients who had low risk scores (TCGA: HR = 3.856, 95% CI [2.297-6.471]; GSE39279: HR = 3.040, 95% CI [1.435-6.437]). This model had a high accuracy in predicting the prognosis (AUC = 0.903 and 0.800, respectively), equivalent to the nomogram model inclusive of clinical variables. Conclusions Referring to the methylation levels of the 16-RNAs might help to predict the survival outcomes in LUSC.
Collapse
Affiliation(s)
- Weiqing Wang
- Department of Thoracic Surgery, The Fifth People’s Hospital of Shanghai, Shanghai, China
| | - Ming Xiang
- Department of Thoracic Surgery, The Fifth People’s Hospital of Shanghai, Shanghai, China
| | - Hui Liu
- Department of Thoracic Surgery, The Fifth People’s Hospital of Shanghai, Shanghai, China
| | - Xiao Chu
- Department of Thoracic Surgery, The Fifth People’s Hospital of Shanghai, Shanghai, China
| | - Zhaoyun Sun
- Department of Thoracic Surgery, The Fifth People’s Hospital of Shanghai, Shanghai, China
| | - Liang Feng
- Department of Thoracic Surgery, The Fifth People’s Hospital of Shanghai, Shanghai, China
| |
Collapse
|
3
|
Gao L, Liu H, Yin N, Zuo S, Jin G, Hu Y, Hu D, Li Y, Song Q, Fei X. BNIPL‑2 expression is correlated with the prognosis and regulates the proliferation of colorectal cancer through CD44. Mol Med Rep 2019; 20:4073-4080. [PMID: 31485655 PMCID: PMC6797997 DOI: 10.3892/mmr.2019.10633] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Accepted: 07/26/2019] [Indexed: 11/10/2022] Open
Abstract
Colorectal cancer (CRC) currently leads to many deaths worldwide. The regulatory mechanism, however, remains largely unclear. In the present study, bioinformatics methods were used to identify genes associated with CRC prognosis and to detect the molecular signals regulating the cell cycle in two CRC cell lines. It was revealed that BNIPL-2 expression was higher in CRC tissues than in adjacent tissue samples. Upregulation of BNIPL-2 was correlated with poor prognosis and the adverse malignant stages T and M. BNIPL-2 was also associated with signaling pathways involved in cancer cell growth. BNIPL-2 overexpression promoted cell proliferation and increased the proportion of cells in the G2/M phase. Knockdown of BNIPL-2 inhibited cell proliferation. CD44 was regulated by BNIPL-2 and promoted cell proliferation. Downregulation of CD44 suppressed cell proliferation and rescued the cell proliferation promoted by BNIPL-2. Overexpression of CD44 restored the cell proliferation suppressed by BNIPL-2 knockdown. The present study not only suggested that BNIPL-2 may be a potential biomarker of CRC but also indicated that BNIPL-2 regulates CRC cancer proliferation via CD44, which could be a diagnostic and clinical treatment target.
Collapse
Affiliation(s)
- Lei Gao
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Hansong Liu
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Ningwei Yin
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Shanshan Zuo
- Department of Anesthesiology, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Guangli Jin
- Department of Anesthesiology, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Yangxi Hu
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Desheng Hu
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Ying Li
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Qiong Song
- Department of Anesthesiology, Zhengzhou Central Hospital Affiliated with Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Xuejie Fei
- Department of Hospital Infections, Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai 200021, P.R. China
| |
Collapse
|
4
|
Mosquera Orgueira A, Antelo Rodríguez B, Alonso Vence N, Díaz Arias JÁ, Díaz Varela N, Pérez Encinas MM, Allegue Toscano C, Goiricelaya Seco EM, Carracedo Álvarez Á, Bello López JL. The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution. BMC Cancer 2019; 19:515. [PMID: 31142279 PMCID: PMC6542042 DOI: 10.1186/s12885-019-5628-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2018] [Accepted: 04/23/2019] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Chronic Lymphocytic Leukemia (CLL) is the most frequent lymphoproliferative disorder in western countries and is characterized by a remarkable clinical heterogeneity. During the last decade, multiple genomic studies have identified a myriad of somatic events driving CLL proliferation and aggressivity. Nevertheless, and despite the mounting evidence of inherited risk for CLL development, the existence of germline variants associated with clinical outcomes has not been addressed in depth. METHODS Exome sequencing data from control leukocytes of CLL patients involved in the International Cancer Genome Consortium (ICGC) was used for genotyping. Cox regression was used to detect variants associated with clinical outcomes. Gene and pathways level associations were also calculated. RESULTS Single nucleotide polymorphisms in PPP4R2 and MAP3K4 were associated with earlier treatment need. A gene-level analysis evidenced a significant association of RIPK3 with both treatment need and survival. Furthermore, germline variability in pathways such as apoptosis, cell-cycle, pentose phosphate, GNα13 and Nitric oxide was associated with overall survival. CONCLUSION Our results support the existence of inherited conditionants of CLL evolution and points towards genes and pathways that may results useful as biomarkers of disease outcome. More research is needed to validate these findings.
Collapse
Affiliation(s)
- Adrián Mosquera Orgueira
- Clinical University Hospital of Santiago de Compostela, Service of Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago de Compostela, 15706, Spain. .,Division of Hematology, SERGAS, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago, Spain. .,University of Santiago de Compostela, Santiago, Spain.
| | - Beatriz Antelo Rodríguez
- Clinical University Hospital of Santiago de Compostela, Service of Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago de Compostela, 15706, Spain.,Division of Hematology, SERGAS, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago, Spain.,University of Santiago de Compostela, Santiago, Spain
| | - Natalia Alonso Vence
- Clinical University Hospital of Santiago de Compostela, Service of Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago de Compostela, 15706, Spain.,Division of Hematology, SERGAS, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago, Spain
| | - José Ángel Díaz Arias
- Clinical University Hospital of Santiago de Compostela, Service of Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago de Compostela, 15706, Spain.,Division of Hematology, SERGAS, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago, Spain
| | - Nicolás Díaz Varela
- Division of Hematology, SERGAS, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago, Spain
| | - Manuel Mateo Pérez Encinas
- Clinical University Hospital of Santiago de Compostela, Service of Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago de Compostela, 15706, Spain.,University of Santiago de Compostela, Santiago, Spain
| | | | | | - Ángel Carracedo Álvarez
- Clinical University Hospital of Santiago de Compostela, Service of Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago de Compostela, 15706, Spain.,Division of Hematology, SERGAS, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago, Spain.,Fundación Pública de Medicina Xenómica, A Coruña, Spain
| | - José Luis Bello López
- Clinical University Hospital of Santiago de Compostela, Service of Hematology and Hemotherapy, 1st floor, Avenida da Choupana s/n, Santiago de Compostela, 15706, Spain.,Division of Hematology, SERGAS, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago, Spain.,University of Santiago de Compostela, Santiago, Spain
| |
Collapse
|
5
|
Ignatieva EV, Yurchenko AA, Voevoda MI, Yudin NS. Exome-wide search and functional annotation of genes associated in patients with severe tick-borne encephalitis in a Russian population. BMC Med Genomics 2019; 12:61. [PMID: 31122248 PMCID: PMC6533173 DOI: 10.1186/s12920-019-0503-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background Tick-borne encephalitis (TBE) is a viral infectious disease caused by tick-borne encephalitis virus (TBEV). TBEV infection is responsible for a variety of clinical manifestations ranging from mild fever to severe neurological illness. Genetic factors involved in the host response to TBEV that may potentially play a role in the severity of the disease are still poorly understood. In this study, using whole-exome sequencing, we aimed to identify genetic variants and genes associated with severe forms of TBE as well as biological pathways through which the identified variants may influence the severity of the disease. Results Whole-exome sequencing data analysis was performed on 22 Russian patients with severe forms of TBE and 17 Russian individuals from the control group. We identified 2407 candidate genes harboring rare, potentially pathogenic variants in exomes of patients with TBE and not containing any rare, potentially pathogenic variants in exomes of individuals from the control group. According to DAVID tool, this set of 2407 genes was enriched with genes involved in extracellular matrix proteoglycans pathway and genes encoding proteins located at the cell periphery. A total of 154 genes/proteins from these functional groups have been shown to be involved in protein-protein interactions (PPIs) with the known candidate genes/proteins extracted from TBEVHostDB database. By ranking these genes according to the number of rare harmful minor alleles, we identified two genes (MSR1 and LMO7), harboring five minor alleles, and three genes (FLNA, PALLD, PKD1) harboring four minor alleles. When considering genes harboring genetic variants associated with severe forms of TBE at the suggestive P-value < 0.01, 46 genes containing harmful variants were identified. Out of these 46 genes, eight (MAP4, WDFY4, ACTRT2, KLHL25, MAP2K3, MBD1, OR10J1, and OR2T34) were additionally found among genes containing rare pathogenic variants identified in patients with TBE; and five genes (WDFY4,ALK, MAP4, BNIPL, EPPK1) were found to encode proteins that are involved in PPIs with proteins encoded by genes from TBEVHostDB. Three genes out of five (MAP4, EPPK1, ALK) were found to encode proteins located at cell periphery. Conclusions Whole-exome sequencing followed by systems biology approach enabled to identify eight candidate genes (MAP4, WDFY4, ACTRT2, KLHL25, MAP2K3, MBD1, OR10J1, and OR2T34) that can potentially determine predisposition to severe forms of TBE. Analyses of the genetic risk factors for severe forms of TBE revealed a significant enrichment with genes controlling extracellular matrix proteoglycans pathway as well as genes encoding components of cell periphery. Electronic supplementary material The online version of this article (10.1186/s12920-019-0503-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elena V Ignatieva
- Laboratory of Evolutionary Bioinformatics and Theoretical Genetics, The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia. .,Novosibirsk State University, Novosibirsk, 630090, Russia.
| | - Andrey A Yurchenko
- Laboratory of Infectious Disease Genomics, The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia
| | - Mikhail I Voevoda
- Novosibirsk State University, Novosibirsk, 630090, Russia.,Research Institute of Internal and Preventive Medicine-Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, 630004, Russia
| | - Nikolay S Yudin
- Laboratory of Infectious Disease Genomics, The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia.,Novosibirsk State University, Novosibirsk, 630090, Russia
| |
Collapse
|
6
|
Yin DEH, Liang XC, Zhao LI, Zhang H, Sun Q, Wang PY, Sun LQ. Jinmaitong decreases sciatic nerve DNA oxidative damage and apoptosis in a streptozotocin-induced diabetic rat model. Exp Ther Med 2015; 10:778-786. [PMID: 26622393 DOI: 10.3892/etm.2015.2543] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Accepted: 02/16/2015] [Indexed: 01/17/2023] Open
Abstract
Diabetic peripheral neuropathy (DPN) is a common chronic complication of diabetes. Jinmaitong (JMT), a Traditional Chinese Medicine, improves certain symptoms of DPN, such as limb pain and numbness. The aim of the present study was to investigate the effects of JMT on DNA oxidative damage and apoptosis in the sciatic nerve of diabetic rats. The rats were divided into a normal and a diabetic group. Diabetes was induced using streptozotocin (60 mg/kg). The diabetic model (DM) rats received vitamin C (0.05 g/kg/day) or JMT [low-dosage (L), 0.44 g/kg/day; medium-dosage (M), 0.88 g/kg/day or high-dosage (H), 1.75 g/kg/day]. After 16 weeks, the mechanical pain threshold of the rats was evaluated. The expression of 8-hydroxy-deoxyguanosine (8-OHdG), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase p22phox, B-cell lymphoma 2 (Bcl-2), caspase 3 and cleaved-poly(ADP-ribose) polymerase 1 (PARP-1) in the sciatic nerve tissues was measured using the reverse transcription-quantitative polymerase chain reaction, immunohistochemistry and western blotting. JMT had no effect on body weight and fasting blood glucose levels. Following treatment, the rats in the JMT groups had an improved pain threshold compared with the DM controls (JMT-L, 52.9±6.5 g; JMT-M, 74.7±9.3 g; and JMT-H, 61.7±2.0 g vs. DM control, 35.32±12.06 g; all P<0.01), while the threshold in the JMT-M rats was similar to that of normal controls (P>0.05). 8-OHdG and NADPH oxidase p22phox expression was significantly decreased in the three JMT groups compared with that in the DM controls (all P<0.05). Following JMT treatment, Bcl-2 levels were increased, while caspase 3 and cleaved-PARP-1 levels were decreased compared with those in the DM controls (all P<0.01). In conclusion, JMT may reduce DNA oxidative damage to the sciatic nerve in diabetic rats, as well as regulate genes involved in peripheral neuronal cell apoptosis, suggesting that JMT could be used to prevent or treat DPN in diabetic patients.
Collapse
Affiliation(s)
- DE-Hai Yin
- Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Beijing 100032, P.R. China
| | - Xiao-Chun Liang
- Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Beijing 100032, P.R. China
| | - L I Zhao
- Department of Nephrology and Endocrinology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, P.R. China
| | - Hong Zhang
- Cell Resource Center, School of Basic Medicine, Peking Union Medical College, Beijing 100005, P.R. China
| | - Qing Sun
- Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Beijing 100032, P.R. China
| | - Pu-Yan Wang
- Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Beijing 100032, P.R. China
| | - Lian-Qing Sun
- Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Beijing 100032, P.R. China
| |
Collapse
|
7
|
BMCC1, which is an interacting partner of BCL2, attenuates AKT activity, accompanied by apoptosis. Cell Death Dis 2015; 6:e1607. [PMID: 25611382 PMCID: PMC4669766 DOI: 10.1038/cddis.2014.568] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Revised: 10/19/2014] [Accepted: 10/30/2014] [Indexed: 11/08/2022]
Abstract
BNIP2 and Cdc42GAP homology (BCH) motif-containing molecule at the carboxyl-terminal region 1 (BMCC1) gene is highly expressed in patients with favorable neuroblastoma (NB). It encodes a 340-kDa protein with a conserved BCH scaffold domain that may regulate signaling networks and multiple cellular functions, including apoptosis. In this study, we determined the mechanism by which BMCC1 promotes apoptosis in human NB and non-NB cells, as BMCC1 is normally expressed in various organs, particularly in neuronal and epithelial tissues. We demonstrated in this report that BMCC1 was induced by DNA damage, one of the triggers of intrinsic apoptosis. Accordingly, we investigated whether BMCC1 expression impacts intracellular signals in the regulation of apoptosis via its C-terminal region containing BCH scaffold domain. BMCC1 decreased phosphorylation of survival signals on AKT and its upstream kinase PDK1. BMCC1 upregulation was correlated with the activation of forkhead box-O3a (FOXO3a) (a downstream inducer of apoptosis, which is suppressed by AKT) and induction of BCL2 inhibitor BIM, suggesting that BMCC1 negatively regulates phosphorylation pathway of AKT, resulted in apoptosis. In addition, we found that BNIP2 homology region of BMCC1 interacts with BCL2. Intrinsic apoptosis induced by DNA damage was enhanced by BMCC1 overexpression, and was diminished by knockdown of BMCC1. Taken together, we conclude that BMCC1 promotes apoptosis at multiple steps in AKT-mediated survival signal pathway. These steps include physical interaction with BCL2 and attenuation of AKT-dependent inhibition of FOXO3a functions, such as transcriptional induction of BIM and phosphorylation of ataxia telangiectasia-mutated (ATM) after DNA damage. We propose that downregulation of BMCC1 expression, which is frequently observed in unfavorable NB and epithelial-derived cancers, may facilitate tumor development by abrogating DNA damage repair and apoptosis.
Collapse
|
8
|
Van Damme P, Plasman K, Vandemoortele G, Jonckheere V, Maurer-Stroh S, Gevaert K. Importance of extended protease substrate recognition motifs in steering BNIP-2 cleavage by human and mouse granzymes B. BMC BIOCHEMISTRY 2014; 15:21. [PMID: 25208769 PMCID: PMC4169252 DOI: 10.1186/1471-2091-15-21] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/09/2014] [Accepted: 08/13/2014] [Indexed: 01/14/2023]
Abstract
Background Previous screening of the substrate repertoires and substrate specificity profiles of granzymes resulted in long substrate lists highly likely containing bystander substrates. Here, a recently developed degradomics technology that allows distinguishing efficiently from less efficiently cleaved substrates was applied to study the degradome of mouse granzyme B (mGrB). Results In vitro kinetic degradome analysis resulted in the identification of 37 mGrB cleavage events, 9 of which could be assigned as efficiently targeted ones. Previously, cleavage at the IEAD75 tetrapeptide motif of Bid was shown to be efficiently and exclusively targeted by human granzyme B (hGrB) and thus not by mGrB. Strikingly, and despite holding an identical P4-P1 human Bid (hBid) cleavage motif, mGrB was shown to efficiently cleave the BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 or BNIP-2 at IEAD28. Like Bid, BNIP-2 represents a pro-apoptotic Bcl-2 protein family member and a potential regulator of GrB induced cell death. Next, in vitro analyses demonstrated the increased efficiency of human and mouse BNIP-2 cleavage by mGrB as compared to hGrB indicative for differing Bid/BNIP-2 substrate traits beyond the P4-P1 IEAD cleavage motif influencing cleavage efficiency. Murinisation of differential primed site residues in hBNIP-2 revealed that, although all contributing, a single mutation at the P3′ position was found to significantly increase the mGrB/hGrB cleavage ratio, whereas mutating the P1′ position from I29 > T yielded a 4-fold increase in mGrB cleavage efficiency. Finally, mutagenesis analyses revealed the composite BNIP-2 precursor patterns to be the result of alternative translation initiation at near-cognate start sites within the 5′ leader sequence (5′UTR) of BNIP-2. Conclusions Despite their high sequence similarity, and previously explained by their distinct tetrapeptide specificities observed, the substrate repertoires of mouse and human granzymes B only partially overlap. Here, we show that the substrate sequence context beyond the P4-P1 positions can influence orthologous granzyme B cleavage efficiencies to an unmatched extent. More specifically, in BNIP-2, the identical and hGrB optimal IEAD tetrapeptide substrate motif is targeted highly efficiently by mGrB, while this tetrapeptide motif is refractory towards mGrB cleavage in Bid.
Collapse
Affiliation(s)
- Petra Van Damme
- Department of Medical Protein Research, VIB, Flanders Interuniversity Institute for Biotechnology, Ghent University, A, Baertsoenkaai 3, B9000 Ghent, Belgium.
| | | | | | | | | | | |
Collapse
|
9
|
Braicu C, Pileczki V, Irimie A, Berindan-Neagoe I. p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol Cell Biochem 2013; 381:61-8. [PMID: 23881244 DOI: 10.1007/s11010-013-1688-5] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 05/16/2013] [Indexed: 01/14/2023]
Abstract
p53 protein is probably the best known tumor suppressor. Earlier reports proved that human breast cancer cells expressing mutant p53 displayed resistance to apoptosis. This study is intended to investigate, the potential applications of RNA interference (RNAi) to block p53 expression, as well as its subsequent effect on cell growth, apoptosis and migration on a triple negative human breast cancer cell line (Hs578T). p53siRNA significantly reduced cell index (CI) compared to the control and we observed an inhibition of cellular migration in the interval of time between 0 and 30 h, as shown in the data obtained by dynamic evaluation using the xCELLigence System. Also, by using PCR-array technology, a panel of 84 key genes involved in apoptosis was investigated. Our studies indicate that the knockdown of p53 expression by siRNA modulates several genes involved in cell death pathways and apoptosis, showing statistically significant gene expression differences for 22 genes, from which 18 were upregulated and 4 were downregulated. The present research also emphasizes the important role of BCL-2 pro-apoptotic family of genes (Bim, Bak, and Bax) in activating apoptosis and reducing cell proliferation by p53siRNA treatment. Death receptors cooperate with BCL-2 pro-apoptotic genes in reducing cell proliferation. The limited success may be due to the activation of the antiapoptotic gene Mcl-1, and it may be associated with the resistance of triple negative breast cancer cells to cancer treatment. Thus, targeting p53siRNA pathways using siRNA may serve as a promising therapeutic strategy for the treatment of breast cancers.
Collapse
Affiliation(s)
- Cornelia Braicu
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
| | | | | | | |
Collapse
|
10
|
Pan CQ, Low BC. Functional plasticity of the BNIP-2 and Cdc42GAP Homology (BCH) domain in cell signaling and cell dynamics. FEBS Lett 2012; 586:2674-91. [DOI: 10.1016/j.febslet.2012.04.023] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2012] [Revised: 04/16/2012] [Accepted: 04/16/2012] [Indexed: 10/28/2022]
|
11
|
Nile AH, Bankaitis VA, Grabon A. Mammalian diseases of phosphatidylinositol transfer proteins and their homologs. CLINICAL LIPIDOLOGY 2010; 5:867-897. [PMID: 21603057 PMCID: PMC3097519 DOI: 10.2217/clp.10.67] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Inositol and phosphoinositide signaling pathways represent major regulatory systems in eukaryotes. The physiological importance of these pathways is amply demonstrated by the variety of diseases that involve derangements in individual steps in inositide and phosphoinositide production and degradation. These diseases include numerous cancers, lipodystrophies and neurological syndromes. Phosphatidylinositol transfer proteins (PITPs) are emerging as fascinating regulators of phosphoinositide metabolism. Recent advances identify PITPs (and PITP-like proteins) to be coincidence detectors, which spatially and temporally coordinate the activities of diverse aspects of the cellular lipid metabolome with phosphoinositide signaling. These insights are providing new ideas regarding mechanisms of inherited mammalian diseases associated with derangements in the activities of PITPs and PITP-like proteins.
Collapse
Affiliation(s)
- Aaron H Nile
- Department of Cell & Developmental Biology, Lineberger Comprehensive Cancer Center School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-27090, USA
| | - Vytas A Bankaitis
- Department of Cell & Developmental Biology, Lineberger Comprehensive Cancer Center School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-27090, USA
| | - Aby Grabon
- Department of Cell & Developmental Biology, Lineberger Comprehensive Cancer Center School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-27090, USA
| |
Collapse
|
12
|
Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, Schormann W, Selinski S, Freis E, Schwender H, Brulport M, Ickstadt K, Rahnenführer J, Maccoux L, West J, Kölbl H, Schuler M, Hengstler JG. ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer. Clin Cancer Res 2010; 16:451-60. [PMID: 20068093 DOI: 10.1158/1078-0432.ccr-09-1617] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Ilka Brigitte Petry
- Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Aoyama T, Hata S, Nakao T, Tanigawa Y, Oka C, Kawaichi M. Cayman ataxia protein caytaxin is transported by kinesin along neurites through binding to kinesin light chains. J Cell Sci 2009; 122:4177-85. [DOI: 10.1242/jcs.048579] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Deficiency of caytaxin results in hereditary ataxia or dystonia in humans, mice and rats. Our yeast two-hybrid screen identified kinesin light chains (KLCs) as caytaxin-binding proteins. The tetratricopeptide-repeat region of KLC1 recognizes the ELEWED sequence (amino acids 115-120) of caytaxin. This motif is conserved among BNIP-2 family members and other KLC-interacting kinesin cargo proteins such as calsyntenins. Caytaxin associates with kinesin heavy chains (KHCs) indirectly by binding to KLCs, suggesting that caytaxin binds to the tetrameric kinesin molecule. In cultured hippocampal neurons, we found that caytaxin is distributed in both axons and dendrites in punctate patterns, and it colocalizes with microtubules and KHC. GFP-caytaxin expressed in hippocampal neurons is transported at a speed (∼1 μm/second) compatible with kinesin movement. Inhibition of kinesin-1 by dominant-negative KHC decreases the accumulation of caytaxin in the growth cone. Caytaxin puncta do not coincide with vesicles containing known kinesin cargos such as APP or JIP-1. A part of caytaxin, however, colocalizes with mitochondria and suppression of caytaxin expression by RNAi redistributes mitochondria away from the distal ends of neurites. These data indicate that caytaxin binds to kinesin-1 and functions as an adaptor that mediates intracellular transport of specific cargos, one of which is the mitochondrion.
Collapse
Affiliation(s)
- Takane Aoyama
- Division of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan
| | - Suguru Hata
- Division of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan
| | - Takeshi Nakao
- Division of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan
| | - Yuka Tanigawa
- Division of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan
| | - Chio Oka
- Division of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan
| | - Masashi Kawaichi
- Division of Gene Function in Animals, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan
| |
Collapse
|
14
|
Debily MA, Marhomy SE, Boulanger V, Eveno E, Mariage-Samson R, Camarca A, Auffray C, Piatier-Tonneau D, Imbeaud S. A functional and regulatory network associated with PIP expression in human breast cancer. PLoS One 2009; 4:e4696. [PMID: 19262752 PMCID: PMC2650800 DOI: 10.1371/journal.pone.0004696] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2008] [Accepted: 01/11/2009] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND The PIP (prolactin-inducible protein) gene has been shown to be expressed in breast cancers, with contradictory results concerning its implication. As both the physiological role and the molecular pathways in which PIP is involved are poorly understood, we conducted combined gene expression profiling and network analysis studies on selected breast cancer cell lines presenting distinct PIP expression levels and hormonal receptor status, to explore the functional and regulatory network of PIP co-modulated genes. PRINCIPAL FINDINGS Microarray analysis allowed identification of genes co-modulated with PIP independently of modulations resulting from hormonal treatment or cell line heterogeneity. Relevant clusters of genes that can discriminate between [PIP+] and [PIP-] cells were identified. Functional and regulatory network analyses based on a knowledge database revealed a master network of PIP co-modulated genes, including many interconnecting oncogenes and tumor suppressor genes, half of which were detected as differentially expressed through high-precision measurements. The network identified appears associated with an inhibition of proliferation coupled with an increase of apoptosis and an enhancement of cell adhesion in breast cancer cell lines, and contains many genes with a STAT5 regulatory motif in their promoters. CONCLUSIONS Our global exploratory approach identified biological pathways modulated along with PIP expression, providing further support for its good prognostic value of disease-free survival in breast cancer. Moreover, our data pointed to the importance of a regulatory subnetwork associated with PIP expression in which STAT5 appears as a potential transcriptional regulator.
Collapse
Affiliation(s)
- Marie-Anne Debily
- Array s/IMAGE, Genexpress, Functional Genomics and Systems Biology for Health, LGN-UMR 7091-CNRS and Pierre & Marie Curie University, Paris VI, Villejuif, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Curwin AJ, McMaster CR. Structure and function of the enigmatic Sec14 domain-containing proteins and the etiology of human disease. ACTA ACUST UNITED AC 2008. [DOI: 10.2217/17460875.3.4.399] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
16
|
Valencia CA, Cotten SW, Liu R. Cleavage of BNIP-2 and BNIP-XL by caspases. Biochem Biophys Res Commun 2007; 364:495-501. [PMID: 17961507 DOI: 10.1016/j.bbrc.2007.10.018] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2007] [Accepted: 10/06/2007] [Indexed: 11/30/2022]
Abstract
BNIP-2 and BNIP-XL are BCH domain-containing proteins that are implicated in programmed cell death. It has been reported that overexpression of BNIP-2 in neuroblastoma cell lines resulted in massive cell death, whereas BNIP-XL was upregulated during NGF-depletion-induced apoptosis in neuroblastoma and was involved in the regulation of differentiation, survival, and aggressiveness of tumor cells. Despite their importance in apoptosis, our understanding of BNIP-2 containing proteins is limited. In this communication, we demonstrate that both BNIP-2 and BNIP-XL are cleaved by caspases during apoptosis. Significantly, the caspase cleavage sites on BNIP-2 are located on its N-terminal EF-hand motif, while that on BNIP-XL is located upstream of the C-terminal BCH domain. Our results suggest that the caspase-mediated cleavage of BNIP-2 and BNIP-XL could result in the release of the BCH domain or smaller fragments that are crucial for their proapoptotic activities.
Collapse
Affiliation(s)
- C Alexander Valencia
- School of Pharmacy and Carolina Center for Genome Sciences, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | | | | |
Collapse
|
17
|
Seong J, Oh HJ, Kim J, An JH, Kim W. Identification of proteins that regulate radiation-induced apoptosis in murine tumors with wild type p53. JOURNAL OF RADIATION RESEARCH 2007; 48:435-41. [PMID: 17721044 DOI: 10.1269/jrr.07015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
In this study, we investigated the molecular factors determining the induction of apoptosis by radiation. Two murine tumors syngeneic to C3H/HeJ mice were used: an ovarian carcinoma OCa-I, and a hepatocarcinoma HCa-I. Both have wild type p53, but display distinctly different radiosensitivity in terms of specific growth delay (12.7 d in OCa-I and 0.3 d in HCa-I) and tumor cure dose 50% (52.6 Gy in OCa-I and > 80 Gy in HCa-I). Eight-mm tumors on the thighs of mice were irradiated with 25 Gy and tumor samples were collected at regular time intervals after irradiation. The peak levels of apoptosis were 16.1 +/- 0.6% in OCa-I and 0.2 +/- 0.0% in HCa-I at 4 h after radiation, and this time point was used for subsequent proteomics analysis. Protein spots were identified by peptide mass fingerprinting with a focus on those related to apoptosis. In OCa-I tumors, radiation increased the expression of cytochrome c oxidase and Bcl2/adenovirus E1B-interacting 2 (Nip 2) protein higher than 3-fold. However in HCa-I, these two proteins showed no significant change. The results suggest that radiosensitivity in tumors with wild type p53 is regulated by a complex mechanism. Furthermore, these proteins could be molecular targets for a novel therapeutic strategy involving the regulation of radiosensitivity.
Collapse
Affiliation(s)
- Jinsil Seong
- Department of Radiation Oncology, Yonsei University Medical College, Seoul, Korea.
| | | | | | | | | |
Collapse
|
18
|
Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006; 43:1-67. [PMID: 16531274 DOI: 10.1080/10408360500295626] [Citation(s) in RCA: 174] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
One of the most effective ways to combat different types of cancer is through early diagnosis and administration of effective treatment, followed by efficient monitoring that will allow physicians to detect relapsing disease and treat it at the earliest possible time. Apoptosis, a normal physiological form of cell death, is critically involved in the regulation of cellular homeostasis. Dysregulation of programmed cell death mechanisms plays an important role in the pathogenesis and progression of cancer as well as in the responses of tumours to therapeutic interventions. Many members of the BCL2 (B-cell CLL/lymphoma 2; Bcl-2) family of apoptosis-related genes have been found to be differentially expressed in various malignancies, and some are useful prognostic cancer biomarkers. We have recently cloned a new member of this family, BCL2L12, which was found to be differentially expressed in many tumours. Most of the BCL2 family genes have been found to play a central regulatory role in apoptosis induction. Results have made it clear that a number of coordinating alterations in the BCL2 family of genes must occur to inhibit apoptosis and provoke carcinogenesis in a wide variety of cancers. However, more research is required to increase our understanding of the extent to which and the mechanisms by which they are involved in cancer development, providing the basis for earlier and more accurate cancer diagnosis, prognosis and therapeutic intervention that targets the apoptosis pathways. In the present review, we describe current knowledge of the function and molecular characteristics of a series of classic but also newly discovered genes of the BCL2 family as well as their implications in cancer development, prognosis and treatment.
Collapse
Affiliation(s)
- Hellinida Thomadaki
- Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, 15701 Athens, Greece
| | | |
Collapse
|
19
|
Zhou YT, Guy GR, Low BC. BNIP-Sα induces cell rounding and apoptosis by displacing p50RhoGAP and facilitating RhoA activation via its unique motifs in the BNIP-2 and Cdc42GAP homology domain. Oncogene 2005; 25:2393-408. [PMID: 16331259 DOI: 10.1038/sj.onc.1209274] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Changes in cell morphology are linked to many cellular events including cytokinesis, differentiation, migration and apoptosis. We recently showed that BNIP-Salpha induced cell rounding that leads to apoptosis via its BNIP-2 and Cdc42GAP Homology (BCH) domain, but the underlying mechanism has not been determined. Here, we have identified a unique region (amino acid 133-177) of the BNIP-Salpha BCH domain that targets RhoA, but not Cdc42 or Rac1 and only the dominant-negative form of RhoA could prevent the resultant cell rounding and apoptotic effect. The RhoA-binding region consists of two parts; one region (residues 133-147) that shows some homology to part of the RhoA switch I region and an adjacent sequence (residues 148-177) that resembles the REM class I RhoA-binding motif. The sequence 133-147 is also necessary for its heterophilic interaction with the BCH domain of the Rho GTPase-activating protein, p50RhoGAP/Cdc42GAP. These overlapping motifs allow tripartite competition such that overexpression of BNIP-Salpha could reduce p50RhoGAP binding to RhoA and restore RhoA activation. Furthermore, BNIP-Salpha mutants lacking the RhoA-binding motif completely failed to induce cell rounding and apoptosis. Therefore, via unique binding motifs within its BCH domain, BNIP-Salpha could interact and activate RhoA while preventing its inhibition by p50RhoGAP. This concerted mechanism could allow effective propagation of the RhoA pathway for cell rounding and apoptosis.
Collapse
Affiliation(s)
- Y T Zhou
- Cell Signaling and Developmental Biology Laboratory, Department of Biological Sciences, The National University of Singapore, Singapore, Republic of Singapore
| | | | | |
Collapse
|
20
|
Xie L, Qin WX, Li JJ, He XH, Shu HQ, Yao GF, Wan DF, Gu JR. cDNA expression array analysis of gene expression in human hepatocarcinoma Hep3B cells induced by BNIPL-1. Acta Biochim Biophys Sin (Shanghai) 2005; 37:618-24. [PMID: 16143817 DOI: 10.1111/j.1745-7270.2005.00086.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Bcl-2/adenovirus E1B 19 kDa interacting protein 2 like-1 (BNIPL-1) is a novel human protein identified in our laboratory, which can interact with Bcl-2 and Cdc42GAP and induce apoptosis via the BNIP-2 and Cdc42GAP homology (BCH) domain. In the present study, we established the Hep3B-Tet-on stable cell line in which expression of BNIPL-1 can be induced by doxycycline. The cell proliferation activity assay showed that the overexpression of BNIPL-1 suppresses Hep3B cell growth in vitro. The differential expression profiles of 588 known genes from BNIPL-1-transfected Hep3B-Tet-on and vector control cells were determined using the Atlas human cDNA expression array. Fifteen genes were differentially expressed between these two cell lines, among which seven genes were up-regulated and eight genes were down-regulated by BINPL-1. Furthermore, the differential expression result was confirmed by semiquantitative RT-PCR. Among these differentially expressed genes, p16INK4, IL-12, TRAIL and the lymphotoxin beta gene involved in growth suppression or cell apoptosis were up-regulated, and PTEN involved in cell proliferation was down-regulated by BNIPL-1. These results suggest that BNIPL-1 might inhibit cell growth though cell cycle arrest and/or apoptotic cell death pathway(s).
Collapse
Affiliation(s)
- Li Xie
- Shanghai Medical College, Fudan University, Shanghai 200032, China
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Wan D, Gong Y, Qin W, Zhang P, Li J, Wei L, Zhou X, Li H, Qiu X, Zhong F, He L, Yu J, Yao G, Jiang H, Qian L, Yu Y, Shu H, Chen X, Xu H, Guo M, Pan Z, Chen Y, Ge C, Yang S, Gu J. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci U S A 2004; 101:15724-9. [PMID: 15498874 PMCID: PMC524842 DOI: 10.1073/pnas.0404089101] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2004] [Accepted: 09/09/2004] [Indexed: 02/02/2023] Open
Abstract
A large-scale assay was performed by transfecting 29,910 individual cDNA clones derived from human placenta, fetus, and normal liver tissues into human hepatoma cells and 22,926 cDNA clones into mouse NIH 3T3 cells. Based on the results of colony formation in hepatoma cells and foci formation in NIH 3T3 cells, 3,806 cDNA species (8,237 clones) were found to possess the ability of either stimulating or inhibiting cell growth. Among them, 2,836 (6,958 clones) were known genes, 372 (384 clones) were previously unrecognized genes, and 598 (895 clones) were unigenes of uncharacterized structure and function. A comprehensive analysis of the genes and the potential mechanisms for their involvement in the regulation of cell growth is provided. The genes were classified into four categories: I, genes related to the basic cellular mechanism for growth and survival; II, genes related to the cellular microenvironment; III, genes related to host-cell systemic regulation; and IV, genes of miscellaneous function. The extensive growth-regulatory activity of genes with such highly diversified functions suggests that cancer may be related to multiple levels of cellular and systemic controls. The present assay provides a direct genomewide functional screening method. It offers a better understanding of the basic machinery of oncogenesis, including previously undescribed systemic regulatory mechanisms, and also provides a tool for gene discovery with potential clinical applications.
Collapse
Affiliation(s)
- Dafang Wan
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Yi Gong
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Wenxin Qin
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Pingping Zhang
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Jinjun Li
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Lin Wei
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Xiaomei Zhou
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Hongnian Li
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Xiaokun Qiu
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Fei Zhong
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Liping He
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Jian Yu
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Genfu Yao
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Huiqiu Jiang
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Lianfang Qian
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Ye Yu
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Huiqun Shu
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Xianlian Chen
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Huili Xu
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Minglei Guo
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Zhimei Pan
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Yan Chen
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Chao Ge
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Shengli Yang
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| | - Jianren Gu
- National Laboratory for Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China; Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China; and BioInfo Bridge, 16905 George Washington Drive, Rockville, MD 20853
| |
Collapse
|